GAO Analysis Refutes Industry Myths About Drug Development |
Rep. Waxman, along with Sens. Durbin and Kennedy, today released a new GAO analysis revealing a decline in new drug development by the pharmaceutical industry. The report contradicts the myth that higher research expenditures have resulted in more treatment options for patients.
The panel of experts convened by GAO recommended increased collaboration among government, industry, and academia in the drug development proces and in the development of scientists who can translate scientific breakthroughs into practical results . The panel also indicated that the government could consider provid ing additional financial incentives — such as longer patent lives for innovative drugs and shorter patent terms for “me-too” drugs — to shape the drug development process. Documents and Links |
Committee On Oversight and Government Reform
U.S. House of Representatives | 2157 Rayburn House Office Building | Washington, D.C. 20515 | (202) 225-5051